Expert Physician Recommendations and Current Practice Patterns for Evaluating and Treating Men with Osteoporotic Hip Fracture
- 1 October 2000
- journal article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 48 (10) , 1261-1263
- https://doi.org/10.1111/j.1532-5415.2000.tb02599.x
Abstract
OBJECTIVES: To develop recommendations for the evaluation and the treatment of men with osteoporotic hip fracture from expert publications in the field of male osteoporosis, and to define the current practice patterns in a tertiary care VA Medical Center in Durham, North Carolina. DESIGN: Survey research; a retrospective cohort study. SETTING: Tertiary care VA Medical Center in Durham, North Carolina. PARTICIPANTS: (1) US physicians who published on the subject of male osteoporosis in the peer‐reviewed literature between 1993 and 1997 identified by MEDLINE database search. (2) All 119 men admitted to the Durham VA Medical Center with ICD9 code for hip fracture between 1994 and 1998. OUTCOME MEASURES: (1) Osteoporosis evaluation and treatment recommendations of published physicians obtained by survey instrument. (2) Actual osteoporosis evaluation completed and therapy prescribed during index hospitalization in a cohort of men with hip fractures, determined by chart and database review. RESULTS: (1) Forty‐three physician‐researchers were surveyed with an 84% response rate. For an osteoporosis evaluation, 89% of respondents recommended measuring serum testosterone, 85% serum calcium, 75% 25‐OH vitamin D levels, 73% myeloma screen, and 61% serum thyroid‐stimulating hormone (TSH). Dual Energy X‐ray Absorptiometry would be obtained by 92%. More than 70% recommended calcium, vitamin D, and bisphosphonates for men with a normal metabolic evaluation, and 60% suggested weight‐bearing exercise. (2) In the cohort of men admitted with hip fractures, 50% had a serum calcium level and 3% had a serum TSH level measured. Vitamin D was prescribed to 25% of patients in the form of a multivitamin, and 4% received calcium. There was no bisphosphonate, testosterone, or calcitonin use. CONCLUSIONS: Physicians who have published on osteoporosis recommended metabolic evaluation and osteoporosis therapy after hip fracture. Only minimal evaluation and treatment occurred in a cohort of men with osteoporotic hip fractures.Keywords
This publication has 19 references indexed in Scilit:
- Physical Activity and Osteoporotic Fracture Risk in Older WomenAnnals of Internal Medicine, 1998
- A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging MenJournal of Bone and Mineral Research, 1998
- Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trialsOsteoporosis International, 1997
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- AETIOLOGY AND PRESENTING SYMPTOMS IN MALE OSTEOPOROSISRheumatology, 1995
- Severe Osteoporosis in MenAnnals of Internal Medicine, 1995
- Vitamin D3and Calcium to Prevent Hip Fractures in Elderly WomenNew England Journal of Medicine, 1992
- Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric studyMaturitas, 1992
- Pathogenesis of Vertebral Crush Fractures in MenAge and Ageing, 1992
- Predictors of Functional Recovery One Year Following Hospital Discharge for Hip Fracture: A Prospective StudyJournal of Gerontology, 1990